<DOC>
	<DOCNO>NCT02527174</DOCNO>
	<brief_summary>This Phase I clinical trial determine maximum tolerate dose ( MTD ) polo-like kinase-1 inhibitor volasertib safely combine idarubicin plus cytarabine induction chemotherapy previously untreated patient acute myeloid leukemia . ( AML ) .</brief_summary>
	<brief_title>A Study Volasertib Plus Induction Chemotherapy Acute Myeloid Leukemia</brief_title>
	<detailed_description>Main inclusion criterion : 1 . AML , subtype except acute promyelocytic leukemia ( APL ) 2 . At least one follow feature : . Age 18-75 adverse risk cytogenetics ii . Age 18-75 antecedent myelodysplastic syndrome ( MDS ) myeloproliferative disorder ( MPD ) , therapy-related AML iii . Age 60-75 , regardless risk category 3 . No prior therapy AML hydroxyurea 4 . Judged treat physician medically fit induction chemotherapy 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0-2 6 . Normal leave ventricular ejection fraction Subjects receive induction chemotherapy consist idarubicin 12 mg/m2 Days 1-3 plus cytarabine 200 mg/m2 ( age 18-59 ) 100 mg/m2 ( age 60-75 ) continuous IV infusion x 7 day . Volasertib administer day 4 dose-escalation schedule , use standard 3+3 dose escalation design , 3 dose level . Once MTD determine , additional dose expansion cohort accrue .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>1 . AML , World Health Organization ( WHO ) subtype except APL , either de novo secondary ; extramedullary AML ( i.e . granulocytic sarcoma ) permit . 2 . At least one follow feature : Age 1875 adverse risk cytogenetics , include : Complete partial deletion chromosome 5 7 Complex karyotype , define &gt; 3 abnormality , exclude ( 15 ; 17 ) . ( 8 ; 21 ) inv ( 16 ) variant 11q23 abnormality Inv ( 3 ) ( q21 ; q26 ) variant ( 6 ; 9 ) abn ( 17p ) Age 1875 secondary AML , define arise antecedent myelodysplastic syndrome ( MDS ) myeloproliferative disorder ( MPD ) , therapyrelated AML Age 6075 , regardless risk category 3 . No prior therapy AML hydroxyurea ( allow 28 day ) . Prior therapy MDS , MPD malignancy allow . 4 . Judged treat physician medically fit induction chemotherapy 5 . ECOG performance status score 02 . 6 . Left ventricular ejection fraction ( LVEF ) within normal limit , myocardial multigated scan ( MUGA ) echocardiogram . 7 . Signed date write informed consent prior admission 1 . Prior anthracycline exposure equivalent &gt; 300 mg/m2 doxorubicin . 2 . Prior chemotherapy radiotherapy within previous four week except hydroxyurea . 3 . Prior treatment volasertib Pololike kinase inhibitor 4 . Known hypersensitivity trial drug 5 . Serum creatinine &gt; 1.5 time ( 1.5x ) upper limit normal ( ULN ) creatinine clearance ( CLcr ) &lt; 30 ml/min ( estimate creatinine clearance CockcroftGault ( CG ) equation 6 . Serum bilirubin &gt; 1.5x ULN , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3x ULN 7 . Persistence clinically relevant therapy relate toxicity previous anticancer therapy 8 . Active central nervous system leukemia ( lumbar puncture require ; clinical judgement sufficient ) 9 . Treatment investigational drug treatment another clinical trial within past 4 week start therapy concomitantly trial 10 . Significant cardiovascular disease ( i.e . uncontrolled hypertension , unstable angina , history infarction within past 12 month prior start study treatment , congestive heart failure ( &gt; New York Heart AssociationII ) , serious cardiac arrhythmia , pericardial effusion ) 11 . QTcF prolongation &gt; 470 m QT prolongation deem clinically relevant investigator ( e.g. , congenital long QT syndrome ) .The QTcF calculate mean 3 ECGs take screening . 12 . Other concurrent malignancy require active therapy ( except hormonal therapy prostate breast cancer ) . 13 . Severe uncontrolled infection . Controlled infection antibiotic permit . 14 . Active chronic hepatitis C and/or B infection 15 . Known HIV infection 16 . Serious illness concomitant nononcological disease neurologic , psychiatric , infectious disease active ulcer ( gastrointestinal tract , skin ) laboratory abnormality may increase risk associate study participation study drug administration judgment investigator would make patient inappropriate entry study . 17 . Patients sexually active unwilling use medically acceptable method contraception ( e.g . implant , injectables , combine oral contraceptive , intrauterine device vasectomize partner participate female , condom participate male ) trial least six month end active therapy study . 18 . Pregnancy breast feeding , female patient must negative pregnancy test prior commence study treatment . 19 . Psychological , familial sociological factor potentially hamper compliance study protocol followup schedule 20 . Known suspect active alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>